KLRC3

KLRC3 encodes NKG2-E, a type II transmembrane C-type lectin-like receptor that covalently heterodimerizes with CD94 to form an activating receptor complex on NK cells and T cell subsets (PMID:9485212). NKG2-E transcript is constitutively expressed in resting CD4+ T cells independently of CD94, distinguishing it from the activation-dependent expression of NKG2-A and NKG2-C, and NKG2-E/NKG2-H splice variants are co-generated at a fixed ratio in NK cell clones where their levels correlate with surface receptor expression and cytotoxicity (PMID:15550116, PMID:12191515). Beyond immune receptor function, KLRC3 promotes glioblastoma cancer stem cell self-renewal, invasion, proliferation, and radioresistance, and in endometrial cancer it acts downstream of ADSL-derived fumarate to drive proliferation and migration (PMID:27641066, PMID:29467457).

1. 1997 Low

   Genomic characterization of the NKG2 family established KLRC3/NKG2-E as a distinct family member with a conserved CD94-interacting motif, predicting its capacity to form heterodimers.

   Evidence Molecular cloning and sequence analysis of NKG2 family genes

   PMID:9394807

   Open questions at the time

   • No direct biochemical or functional validation of NKG2-E heterodimer formation was performed
   • Expression pattern of KLRC3 was not characterized
   • Signaling capacity of NKG2-E was not tested
2. 1998 High

   Biochemical reconstitution demonstrated that NKG2-C (closely related to NKG2-E) covalently associates with CD94 to form an activating receptor, and the KLRC gene cluster including KLRC3 was physically mapped to chromosome 12p12.3-p13.2 within the NK gene complex.

   Evidence Co-transfection in COS7 cells, immunoprecipitation, peptide mapping, redirected killing assays; genomic sequencing of 62-kb region

   PMID:9485212 PMID:9598306

   Open questions at the time

   • NKG2-E itself was not directly reconstituted as a CD94 partner in this study
   • Ligand specificity of a putative CD94/NKG2-E complex was unknown
   • Signaling adaptor usage by NKG2-E was not determined
3. 2002 Medium

   Quantitative expression analysis linked NKG2-E transcript levels to surface receptor expression and NK cell cytotoxicity, establishing NKG2-E as functionally relevant in NK clones and revealing a fixed splicing ratio with NKG2-H.

   Evidence Quantitative real-time RT-PCR, flow cytometry, and redirected ADCC on NK cell clones

   PMID:12191515

   Open questions at the time

   • Whether NKG2-E protein itself contributes to cytotoxicity or merely marks receptor-expressing cells was not resolved
   • NKG2-E surface protein was not directly detected with a specific antibody
   • Mechanism controlling the fixed NKG2-E/NKG2-H splice ratio was unexplored
4. 2004 Medium

   NKG2-E was found to be constitutively expressed in resting CD4+ T cells independent of CD94, distinguishing its regulation from the activation-dependent NKG2-A and NKG2-C programs and implying a distinct role in adaptive immunity.

   Evidence RT-PCR on purified human CD4+ and CD8+ T cells, flow cytometry, cytokine measurement after receptor occupancy

   PMID:15550116

   Open questions at the time

   • Functional consequence of constitutive NKG2-E expression in CD4+ T cells was not directly tested
   • Whether NKG2-E pairs with an alternative partner in the absence of CD94 was unresolved
   • Transcriptional regulation driving constitutive NKG2-E expression was not identified
5. 2016 Medium

   Loss-of-function experiments revealed a non-immune role for KLRC3 in glioblastoma, where its silencing reduced cancer stem cell self-renewal, invasion, proliferation, radioresistance, and in vivo tumourigenicity.

   Evidence siRNA knockdown in U87-MG glioblastoma cells with sphere formation, invasion, proliferation, and xenograft assays

   PMID:27641066

   Open questions at the time

   • Downstream signaling pathway mediating KLRC3's pro-tumorigenic effects was not identified
   • Whether KLRC3 acts as a receptor or through a receptor-independent mechanism in cancer cells was unknown
   • Single cell line used; generalizability across glioblastoma models not established
6. 2018 Medium

   Epistasis experiments placed KLRC3 downstream of ADSL-derived fumarate in endometrial cancer, showing that fumarate upregulates KLRC3 to promote proliferation, migration, and invasion.

   Evidence siRNA knockdown of ADSL and KLRC3 with fumarate rescue, DNA microarray, RT-PCR, proliferation and invasion assays in endometrial cancer cells

   PMID:29467457

   Open questions at the time

   • Mechanism by which fumarate regulates KLRC3 transcription (e.g., epigenetic modification, transcription factor activation) was not determined
   • Whether KLRC3's cancer-promoting function operates through its extracellular lectin domain or intracellular signaling was unclear
   • In vivo validation of the ADSL–fumarate–KLRC3 axis in endometrial cancer was not performed

• The ligand specificity of a CD94/NKG2-E complex, the signaling adaptor it engages, the mechanism by which KLRC3 promotes cancer aggressiveness, and the transcriptional basis for its constitutive expression in CD4+ T cells all remain unresolved.
• No HLA-E or other ligand binding data exist specifically for CD94/NKG2-E
• Signaling adaptor (e.g., DAP12 vs DAP10) usage by NKG2-E has not been demonstrated
• Structural basis for NKG2-E function is absent